Minzhi Xing1, Sonali Sakaria2, Renumathy Dhanasekaran3, Samir Parekh2, James Spivey2, Stuart J Knechtle4, Di Zhang5, Hyun S Kim6,7. 1. Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT, 06510, USA. 2. Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 3. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA. 4. Division of Transplant Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC, USA. 5. Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 6. Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, P.O. Box 208042, New Haven, CT, 06510, USA. kevin.kim@yale.edu. 7. Yale Cancer Center, New Haven, CT, USA. kevin.kim@yale.edu.
Abstract
BACKGROUND AND AIMS: To evaluate the long-term survival benefit of bridging locoregional therapy (LRT) prior to orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC) within Milan criteria. METHODS: Our transplant center registry was studied for all HCC patients within the Milan criteria who were listed for OLT from 1998 to 2013. Baseline clinical characteristics and median overall survival (OS) were calculated and stratified by LRT, OLT status, and wait times. Survival analysis was conducted using Kaplan-Meier estimation and log-rank test. RESULTS: Of 265 listed, 205 underwent OLT (mean follow-up 7.6 years). Of 205, 111 received bridging LRT (A), and 94 did not (B). Both were similar in demographics and tumor characteristics (p > 0.05). Median OS from HCC for A/B were 86.4 vs. 68.9 months (p = 0.01). Median OS from OLT for A/B were 74.6 vs. 63.6 months (p = 0.03). On multivariate analysis, independent predictors for survival from HCC were bridging LRT (p = 0.002) and high wait time (p = 0.008); independent predictors for survival from OLT were bridging LRT (p = 0.005) and high wait time (p = 0.005). Of 60 who were listed but did not undergo transplant, 44 received LRT (C) and 16 received best supportive care (D). Median OS from HCC for C/D were 37.1 vs. 24.8 months (p = 0.03). CONCLUSIONS: Bridging LRT and high wait times were independent positive prognostic factors for survival from HCC diagnosis and OLT.
BACKGROUND AND AIMS: To evaluate the long-term survival benefit of bridging locoregional therapy (LRT) prior to orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC) within Milan criteria. METHODS: Our transplant center registry was studied for all HCC patients within the Milan criteria who were listed for OLT from 1998 to 2013. Baseline clinical characteristics and median overall survival (OS) were calculated and stratified by LRT, OLT status, and wait times. Survival analysis was conducted using Kaplan-Meier estimation and log-rank test. RESULTS: Of 265 listed, 205 underwent OLT (mean follow-up 7.6 years). Of 205, 111 received bridging LRT (A), and 94 did not (B). Both were similar in demographics and tumor characteristics (p > 0.05). Median OS from HCC for A/B were 86.4 vs. 68.9 months (p = 0.01). Median OS from OLT for A/B were 74.6 vs. 63.6 months (p = 0.03). On multivariate analysis, independent predictors for survival from HCC were bridging LRT (p = 0.002) and high wait time (p = 0.008); independent predictors for survival from OLT were bridging LRT (p = 0.005) and high wait time (p = 0.005). Of 60 who were listed but did not undergo transplant, 44 received LRT (C) and 16 received best supportive care (D). Median OS from HCC for C/D were 37.1 vs. 24.8 months (p = 0.03). CONCLUSIONS: Bridging LRT and high wait times were independent positive prognostic factors for survival from HCC diagnosis and OLT.
Authors: L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu Journal: Curr Oncol Date: 2020-11-01 Impact factor: 3.677
Authors: Mohammad Kamal Shaker; Iman F Montasser; Mohamed Sakr; Mohamed Elgharib; Hany M Dabbous; Hend Ebada; Ahmed El Dorry; Mohamed Bahaa; Mahmoud El Meteini Journal: J Hepatocell Carcinoma Date: 2018-02-27
Authors: Joseph J Titano; Aaron M Fischman; Arnav Cherian; Madeline Tully; Lance L Stein; Louis Jacobs; Raymond A Rubin; Michael Bosley; Steve Citron; Dean W Joelson; Roshan Shrestha; Aravind Arepally Journal: Cardiovasc Intervent Radiol Date: 2019-01-11 Impact factor: 2.740
Authors: Breno Boueri Affonso; Francisco Leonardo Galastri; Joaquim Mauricio da Motta Leal Filho; Felipe Nasser; Priscila Mina Falsarella; Rafael Noronha Cavalcante; Marcio Dias de Almeida; Guilherme Eduardo Gonçalves Felga; Leonardo Guedes Moreira Valle; Nelson Wolosker Journal: World J Gastroenterol Date: 2019-10-07 Impact factor: 5.742